Clinicians should consider the impact on subsequent therapies, overall survival, and median time to definitive deterioration with CDK 4/6 inhibitors.
MBCC - Miami Breast Cancer Conference
Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.
Advertisement
The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5
